因塞特 INCY 深 滬
等待開盤 11-07 09:30:00 美东时间
105.20
-0.500
-0.47%
華盛通- 最 高106.43
- 今 開106.29
- 成交量 239.24万股
- 最 低 103.0201
- 昨 收 105.70
- 總市值 205.14亿
- 52周最高 106.47
- 市盈率 靜 679.15
- 換手率 1.23%
- 52周最低 53.56
- 委 比 -78.37%
- 總股本 1.95亿
- 歷史最高 153.15
- 量 比 0.69
- 振 幅 3.23%
- 歷史最低 11.76
- 每 手 1
- 風險率 9.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Market-Moving News for November 4th
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms NSP: -32% | Insperity shares are trading
11-04 20:24
Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms
Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive option agreement with Incyte (Nasdaq:INCY) focused on Prelude's previously undisclosed mutant
11-04 20:07
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics has entered into an exclusive option agreement with Incyte Corporation for its JAK2V617F mutant selective inhibitor program, involving a $35 million upfront payment, a $25 million equity investment, and potential additional funds if the option is exercised. The company is prioritizing development of its KAT6A selective degrader program for ER+ breast cancer, targeting clinical development in 2026, while pausing its SMARCA2 pr...
11-04 12:05
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points ...
11-04 03:13
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
Guggenheim analyst Michael Schmidt upgrades Incyte (NASDAQ:INCY) from Neutral to Buy and announces $125 price target.
11-04 01:11
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported $45.9 million in third-quarter revenue, up 21% from Q2, driven by strong demand for Revuforj and Niktimvo. Revuforj net revenue rose 12% to $32.0 million, with prescriptions up 25% to 850. Niktimvo net revenue was $45.8 million, yielding $13.9 million in collaboration revenue for Syndax. The FDA approved Revuforj for R/R NPM1m AML on October 24, marking it as the first and only approved therapy for both R/R AML and...
11-03 21:01
